For years finerenone was approved for one thing: CKD with…

For years finerenone was approved for one thing: CKD with type 2 diabetes. Three major studies published simultaneously in NEJM, JAMA and The Lancet just changed everything. The FIND-CKD Phase 3 trial tested finerenone in non-diabetic patients with CKD, reducing the risk of kidney failure, CKD progression, heart failure or cardiovascular death by 23 percent. Non-diabetic CKD. That is an entirely new patient population. A second study extended the findings to patients with CKD caused by glomerular diseases, a category of kidney disorders that affects the filtering units of the kidneys and has historically had few effe